Loading clinical trials...
Loading clinical trials...
A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Nycomed Deutschland GmbH
Aachen, Germany
Nycomed Deutschland GmbH
Adendorf, Germany
Nycomed Deutschland GmbH
Aichach, Germany
Nycomed Deutschland GmbH
Albstadt, Germany
Nycomed Deutschland GmbH
Albstadt-Ebingen, Germany
Nycomed Deutschland GmbH
Altenkirchen, Germany
Nycomed Deutschland GmbH
Aschaffenburg, Germany
Nycomed Deutschland GmbH
Aschersleben, Germany
Nycomed Deutschland GmbH
Augsburg, Germany
Nycomed Deutschland GmbH
Augsburg, Germany
Start Date
September 1, 2009
Primary Completion Date
September 1, 2010
Completion Date
November 1, 2010
Last Updated
September 27, 2012
131
ACTUAL participants
Instanyl (Intranasal Fentanyl)
DRUG
Lead Sponsor
Takeda
NCT06345508
NCT06305754
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05884320